Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 2, 2005 - Issue 5
Submit an article Journal homepage
274
Views
52
CrossRef citations to date
0
Altmetric
Review

Oral pulsatile drug delivery systems

Alessandra Maroni Istituto di Chimica Farmaceutica e Tossicologica, Università di Milano, V. le Abruzzi 42, I-20131 Milan, Italy. [email protected]
,
Lucia Zema Istituto di Chimica Farmaceutica e Tossicologica, Università di Milano, V. le Abruzzi 42, I-20131 Milan, Italy. [email protected]
,
Matteo Cerea Istituto di Chimica Farmaceutica e Tossicologica, Università di Milano, V. le Abruzzi 42, I-20131 Milan, Italy. [email protected]
&
Maria Edvige Sangalli Istituto di Chimica Farmaceutica e Tossicologica, Università di Milano, V. le Abruzzi 42, I-20131 Milan, Italy. [email protected]
Pages 855-871 | Published online: 16 Sep 2005

Bibliography

  • DAVIS SS, ILLUM L: Drug delivery systems for challenging molecules. Int. .1. Pharm. (1998) 176(0:1–8.
  • SMOLENSKY MH: Chronobiology and chronotherapeutics. Applications to cardiovascular medicine. Am. J. Hypertens. (1996) 9 (4II) :11s–21s.
  • LEMMER B: The clinical relevance of chronopharmacology in therapeutics. Pharmacol Res. (1996) 33(2):107–115.
  • •The rationale behind a novel chronopharmaceutical approach in the management of disease is outlined in this paper.
  • SMOLENSKY MH, REINBERG AE, MARTIN RJ, HAUS E: Clinical chronobiology and chronotherapeutics with application to asthma. Chronobiol Int. (1999) 16(5):539–563.
  • •This paper outlines the rationale behind a novel chronopharmaceutical approach in the management of bronchial asthma.
  • CHIEN YW: Controlled- and modulated-release drug-delivery systems. In: Encyclopedia of Pharmaceutical Technology. J S JC Boylan (Eds), Marcel Dekker, New York, NY, USA (1990):281–313.
  • YOUAN BBC: Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery?' Control. Release (2004) 98(3)337–353.
  • •This article highlights the benefits of pharmacological chronotherapy and presents an array of relevant formulation approaches.
  • LEMMER B: Chronopharmacokinetics: implications for drug treatment. J. Pharm. Pharmacol (1999) 51(8):887–890.
  • •This paper discusses the impact of circadian rhythms on pharmacokinetics and, consequently, on the outcome of drug therapies.
  • LEMMER B: Circadian rhythms and drug delivery. J. Control. Release (1991) 16(1-2):63–74.
  • ••This author, particularly as far as the abovepaper is concerned, is considered as a pioneer of chronotherapy.
  • HRUSHESKY WJ: Timing is everything. Sciences. (1994) 34(4):32–37.
  • ••This paper is considered as a milestone inthe field of chronotherapy.
  • LEMMER B: Chronopharmacological aspects for the prevention of acute coronary syndromes. Eur. Heart J. (1998) 19(C):50–58.
  • •This paper outlines the rationale behind a novel chronopharmaceutical approach in the management of ischaemic heart disease.
  • BUSSEMER T, OTTO I, BODMEIER R: Pulsatile drug-delivery systems. Crit. Rev Ther. Drug Carrier Syst. (2001) 18(5):433–458.
  • •This is a comprehensive, clearly exposed review on pulsatile delivery systems dated 2001.
  • GOTHOSKAR AV, JOSHI AM, JOSHI NH: Pulsatile drug delivery systems: a review. Drug Del. Technol. (2004) 4(5).
  • STUBBE BG, SMEDT SC, DEMEESTER J: 'Programmed polymeric devices' for pulsed drug delivery. Pharm. Res. (2004) 21(10):1732–1740.
  • SIEGEL RA, PITT CG: A strategy for oscillatory drug release. General scheme and simplified theory. J. Control. Release (1995) 33(1):173–188.
  • MORMONT M- LEVI F: Chronomodulation of cancer chemotherapy: achievements and perspectives. Drug Del. Syst. Sci. (2001) 1(2):48–51.
  • ERIGUCHI M, LEVI F, HISA T et al: Chronotherapy for cancer. Biomed. Pharmacother. (2003) 57\(Suppl. 1):92s–95s.
  • VYAS SP, SOOD A, VENUGOPALAN P, MYSORE N: Circadian rhythm and drug delivery design. Pharmazie (1997) 52(10:815–820.
  • PRISANT LM: Hypertension and chronotherapy: shifting the treatment paradigm. Am. I Hypertens. (2001) 14(910:277s–279s.
  • PRISANT LM, ELLIOTT WJ: Drug delivery systems for treatment of systemic hypertension. Clin. Pharmacokiriet. (2003) 42(10:931–940.
  • GAZZANIGA A, GIORDANO F, SANGALLI ME, ZEMA L: Oral colon-specific drug delivery: design strategies. S.TP Pharma Prat. (1994) 4(5):336–343.
  • LEOPOLD CS: Coated dosage forms for colon-specific drug delivery. Pharm. Technol Today (1999) 2(5):197–204.
  • DAVIS SS: The design and evaluation of controlled release systems for the gastro-intestinal tract. J. Control. Release (1985) 2:27–38.
  • ••This paper is considered as the cue for the time-dependent formulation approach to colon delivery (i.e., for the exploitation of pulsatile delivery systems to achieve colonic release of drugs).
  • RUBINSTEIN A, TIROSH B, BALUOM M et al.: The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools. Control. Release (1997) 46(1-2):59–73.
  • BODMEIER R: Tableting of coated pellets. Eur. Pharm. Biopharm. (1997) 43(1):1–8.
  • BUSSEMER T, DASHEVSKY A, BODMEIER R: A pulsatile drug delivery system based on rupturable coated hard gelatin capsules." Control. Release (2003) 93(3):331–339.
  • •This paper describes the preparation and in vitro performances of rupturable systems based on hard-gelatin capsules. The interest in the above article is further increased by the considerable experience of the authors in the field.
  • DASHEVSKY A, BUSSEMER T, MOHAMAD A, BODMEIER R: Process and formulation variables affecting the performance of a rupturable capsule-based drug delivery system with pulsatile drug release. Drug Dev.Pharm. (2004)30(2):171–179.
  • BUSSEMER T, BODMEIER R: Formulation parameters affecting the performance of coated gelatin capsules with pulsatile release profiles. Int. I Pharm. (2003) 267(1-2):59–68.
  • •This paper describes the preparation and in vitro performances of rupturable systems based on soft-gelatin capsules.
  • SUNGTHONGJEEN S, PUTTIPIPATKHACHORN S, PAERATAKUL 0, DASHEVSKY A, BODMEIER R: Development of pulsatile release tablets with swelling and rupturable layers. J. Control. Release (2004) 95(2):147–159.
  • BUSSEMER T, PEPPAS NA, BODMEIER R: Time-dependent mechanical properties of polymeric coatings used in rupturable pulsatile release dosage forms. Drug Dev. Ind. Pharm. (2003) 29(6):623–630.
  • BUSSEMER T, PEPPAS NA, BODMEIER R: Evaluation of the swelling, hydration and rupturing properties of the swelling layer of a rupturable pulsatile drug delivery system. Eur. I Pharm. Biopharm. (2003) 56(2):261–270.
  • MORITA R, HONDA R, TAKAHASHI Y: Development of oral controlled release preparations, a PVA swelling controlled release system (SCRS) I. Design of SCRS and its release controlling factor. J. Control. Release (2000) 63(3):297–304.
  • FAN TY, WET SL, YAN WW, CHEN DB, LI J: An investigation of pulsatile release tablets with ethylcellulose and Eudragit® L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. Control. Release (2001) 77(3):245–251.
  • ISHINO R, YOSHINO H, HIRAKAWA Y, NODA K: Design and preparation of pulsatile release tablet as a new oral drug delivery system. Chem. Pharm. Bull. (1992) 40(10:3036–3041.
  • ISHINO R, YOSHINO H, HIRAKAWA Y, NODA K: Absorption of diltiazem in beagle dog from pulsatile release tablet. Chem. Pharm. Bull. (1992) 40(11):3094–3096.
  • ZHANG Y, ZHANG Z, WU F: A novel pulsed-release system based on swelling and osmotic pumping mechanism../. Control. Release (2003) 89(1):47–55.
  • LIN S- LIN K- LI M-J: Micronized ethylcellulose used for designing a directly compressed time-controlled disintegration tablet. J. Control. Release (2001) 70(3):321–328.
  • LIN K- LIN S- LI M-J: Compression forces and amount of outer coating layer affecting the time-controlled disintegration of the compression-coated tablets prepared by direct compression with micronized ethylcellulose. Pharm. Sci. (2001) 90(12):2005–2009.
  • LIN S- LIN K- LI M-J: Influence of excipients, drugs, and osmotic agent in the inner core on the time-controlled disintegration of compression-coated ethylcellulose tablets. J. Pharm. Sci. (2002) 91(9):2040–2046.
  • LIN S- LI M- LIN K-H: Hydrophilic excipients modulate the time lag of time-controlled disintegrating press-coated tablets. AAPS PharmSciTech. (2004) 5(4):1–5.
  • LIN S- LIN K- LI M-J: Formulation design of double-layer in the outer shell of dry-coated tablet to modulate lag time and time-controlled dissolution function: studies on micronized ethylcellulose for dosage form design (VII). AAPS J. (2004) 6(3):17.
  • KROGEL I, BODMEIER R: Floating or pulsatile drug delivery systems based oncoated effervescent cores. Int. J. Pharm. (1999) 187(2):175–184.
  • •This paper describes the preparation of a particular rupturable system, in which effervescent excipients have been exploited as the agents responsible for the core expansion finally resulting in the time-dependent disruption of the outer film.
  • UEDA S, HATA T, ASAKURA S et al: Development of a novel drug release system, time-controlled explosion system (TES). I. Concept and design. I Drug. Target. (1994) 2(1):35–44.
  • •This paper introduces the TES, which is the first example of multiple-unit delivery system for pulsatile release. TES is based on a highly swellable polymer as the expansion agent responsible for disruption of the ethylcellulose film.
  • UEDA S, YAMAGUCHI H, KOTANI M et al: Development of a novel drug release system, time-controlled explosion system (TES). II. Design of multiparticulate TES and in vitro drug release properties. Chem. Pharm. Bull. (1994) 42(2):359–363.
  • UEDA S, IBUKI R, KIMURA S et al: Development of a novel drug release system, time-controlled explosion system (TES). III. Relation between lag time and membrane thickness. Chem. Pharm. Bull. (1994) 42(2):364–367.
  • HATA T, SHIMAZAKI Y, KAGAYAMA A, TAMURA S, UEDA S: Development of a novel drug release system, time-controlled explosion system (TES). V. Animal pharmacodynamic study and human bioavailability study. Int. J. Pharm. (1994) 110(0:1–7.
  • KOK PJA, VONK P, HOEKZEMA MA, KOSSEN NWF: Development of particulate pulse-release formulations and their mathematical description. Powder 7echnol. (2001) 119(0:33–44.
  • SCHULTZ P, KLEINEBUDDE P: A new multiparticulate delayed release system. Part I: dissolution properties and release mechanism../. Control. Release (1997) 47(2):181–189.
  • •These authors describe the preparation and in vitro performances of a multiparticulate delivery system in pellets for pulsatile release, in which osmotic agents are exploited to induce mechanical disruption of the outer release-controlling film.
  • SCHULTZ P, THO I, KLEINEBUDDE P: A new multiparticulate delayed release system. Part II: coating formulation and properties of free films. I Control. Release (1997) 47(2):191–199.
  • MATSUO M, NAKAMURA C, ARIMORI K, NAKANO M: Evaluation of hydroxyethylcellulose as a hydrophilic swellable material for delayed-release tablets. Chem. Pharm. Bull. (1995) 43(2):311–314.
  • MATSUO M, ARIMORI K, NAKAMURA C, NAKANO M: Delayed-release tablets using hydroxyethylcellulose as a gel-forming matrix. Int. J. Pharm. (1996) 138(2):225–235.
  • FUKUI E, UEMURA K, KOBAYASHI M: Studies on applicability of press-coated tablets using hydroxypropylcellulose (HP C) in the outer shell for timed-release preparations. ./. Control. Release (2000) 68(2):215–223.
  • MAFFIONE G, IAMARTINO P, GAZZANIGA A: High-viscosity HPMC as a film-coating agent. 10th Pharmaceutical Technology Conference. Bologna, Italy (1991) 3:66.
  • •This work describes the first experiments reported in the literature on spray-coating based on high-viscosity HPMC aimed at the attainment of swellable/erodible delayed-release systems.
  • GAZZANIGA A, IAMARTINO P, MAFFIONE G, SANGALLI ME: Oral delayed-release system for colonic specific delivery. 6th International Conference on Pharmaceutical Technology. Paris, France (1992) V:305.
  • MAFFIONE G, IAMARTINO P, GUGLIELMINI G, GAZZANIGA A: High-viscosity HPMC as a film-coating agent. Drug Dev. Ind. Pharm. (1993) 19(16):2043–2053.
  • GAZZANIGA A, IAMARTINO P, MAFFIONE G et al.: Rivestimento rigonfiabile idrofilo per il rilascio ritardato di farmaci (delayed-release systems). Boll. Chim. Farm. (1993) 132(2):66–69.
  • GAZZANIGA A, IAMARTINO P, MAFFIONE G, SANGALLI ME: Sistema orale a cessione ritardata per il rilascio al colon. Boll. Chim. Farm. (1993) 132 (3):78–80.
  • GAZZANIGA A, SANGALLI ME, GIORDANO F: Oral Chronotopic® drug delivery systems: achievement of time and/ or site specificity. Eur. j Pharm. Biopharm. (1994) 40(4):246–250.
  • GAZZANIGA A, IAMARTINO P, MAFFIONE G, SANGALLI ME: Oral delayed-release system for colonic specific delivery. Int. J. Pharm. (1994) 108(1):77–83.
  • GAZZANIGA A, BUSETTI C, MORO L, SANGALLI ME, GIORDANO F: Time-dependent oral delivery systems for colon targeting. S. ER Pharma Sri. (1995) 5(1):83–88.
  • •In this paper, the feasibility of HPMC-based aqueous spray-coating procedures is explored for the first time in the preparation of swellable/erodible pulsatile release systems.
  • SANGALLI ME, MARONI A, ZEMA L et al.: Li vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J. Control. Release (2001) 73(1):103–110.
  • •This paper points out the benefits, in terms of both process feasibility and in vitro/ in vivo performances, provided by low-viscosity HPMC employed as an aqueous spray-coating agent for the preparation of swellable/erodible pulsatile release systems.
  • SANGALLI ME, MARONI A, FOPPOLI A et al.: Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: a study on process parameters and in vitro performances. Eur. I Pharm. Sri. (2004) 22(5):469–476.
  • MARONI A, SANGALLI ME, CEREA M et al.: Low viscosity HPMC coating of soft and hard gelatin capsules for delayed and colonic release: preliminary investigations on process parameters and in vitro release performances. Proceedings of the 26th International Symposium on Controlled Release of Bioactive Materials. Boston, MA, USA (1999) 6320.
  • •This work explores the preparation and in vitro performances of swellable/erodible pulsatile release systems obtained from soft- and hard-gelatin capsules.
  • MARONI A, CEREA M, GERVASUTTI C et al.: LI vitro and in vivo evaluation of HPMC-coated hard gelatin capsules for oral time-controlled release. AAPS PharmSci. (2001) 3(3):T3120.
  • •This work focuses on the in vitro/in vivo performances of swellable/erodible pulsatile release systems based on hard-gelatin capsule cores.
  • PIRULLI V, CEREA M, MARONI A et al: HPMC-coating of tablets in tangential-spray rotary fluid bed for the achievement of an oral time and/or site-controlled delivery system. Proceedings of the 31st International Symposium on Controlled Release of Bioactive Materials. HI USA (2004).
  • •An alternative technique, such as tangential spray-coating in rotary fluid bed, is explored for the application of swellable/erodible release-delaying coats onto solid dosage forms
  • CEREA M, SERRATONI M, PALUGAN L et al: Powder-layering technique for the preparation of the HPMC-based retarding coating of an oral system for pulsatile and/or colon-specific release. AAPS Pharm. Sci. (2003) 5(4):W5135.
  • •This work discusses the application of another alternative technique (i.e., powder layering) for the application of swellable/ erodible release-delaying coats onto solid dosage forms.
  • SANGALLI ME, MARONI A, CEREA M et al.: Pharmacoscintigraphic investigation into the performances of a 5-ASA-containing oral system for colon targeting. Proceedings of the International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Nuremberg, Germany (2004):815.
  • CONTE U, MAGGI L, GIUNCHEDI P, MANNA A: New oral system for timing-release of drugs. Boll. Chim. Farm. (1992) 131(5):199–204.
  • CONTE U, MAGGI L, TORRE ML, GIUNCHEDI P, MANNA A: Press-coated tablets for time-programmed release of drugs. Biomaterials (1993) 14(13):1017–1023.
  • HALSAS M, ERVASTI P, VESKI P, JORJENSON H, MARVOLA M: Biopharmaceutical evaluation of time-controlled press-coated tablets containing polymers to adjust drug release. Eur. J. Drug Metab. Pharmacokinet. (1998) 23(2):190–196.
  • HALSAS M, SIMELIUS R, KIVINIEMI A et al.: Effect of different combinations of hydroxypropylmethyl cellulose on bioavailability of ibuprofen from press-coated time-controlled tablets. S.TP Pharma Sci. (1998) 8(3):155–161.
  • HALSAS M, PENTTINEN T, VESKI P, JORJENSON H, MARVOLA M: Time-controlled release pseudoephedrine tablets: bioavailability and in vitro I in vivo correlations. Pharmazie (2001) 56(9):718–723.
  • CAO Q- CHOI H- KIM D- LEE B-J: Release behavior and photo-image of nifedipine tablet coated with high viscosity grade hydroxypropylmethylcellulose: effect of coating conditions. Lk. Pharm. (2004) 274(1-2):107–117.
  • TAKEUCHI H, YASUJI T, YAMAMOTO H, KAWASHIMA Y: Spray-dried lactose composite particles containing an ion complex of alginate-chitosan for designing a dry-coated tablet having a time-controlled releasing function. Pharm. Res. (2000) 17(1):94–99.
  • HARIHARAN M, GUPTA VK: ENCORE: A novel compression-coated tablet dosage form. Proceedings of the 28th International Symposium on Controlled Release of Bioactive Materials. San Diego, USA (2001): 6102.
  • OZEKI Y, ANDO M, WATANABE A, DANJO K: Evaluation of novel one-step dry-coated tablets as a platform for delayed-release tablets. Control. Release (2004) 95(1):51–60.
  • CONTE U, COLOMBO P, LA MANNA A et al.: A new ibuprofen pulsed release oral dosage form. Drug Dev. Ind. Pharm. (1989) 15(14-16):2583–2596.
  • •This paper reports on the initial attempts to prepare swellable/erodible polymeric coatings by double-compression technique. In addition, the resulting system is the first example of multilayered tablet provided with a partial outer coating designed to afford single- or multiple-pulse delayed delivery of drugs.
  • CONTE U, GIUNCHEDI P, MAGGI L et al: Ibuprofen delayed release dosage forms: a proposal for the preparation of an in vitro/in vivo pulsatile system. Eur. Pharm. Biopharm. (1992) 38(6):209–212.
  • MAGGI L, CONTE U, BRUNT R: Delivery device for the release of the active ingredient in subsequent times. Proceedings of the 26th International Symposium on Controlled Release of Bioactive Materials. Boston, USA (1999): 5926.
  • VANDELLI MA, LEO E, FORNI F, BERNABEI MT: In vitro evaluation of a potential colonic delivery system that releases drug after a controllable lag-time. Eur. I Pharm. Biopharm. (1996) 43(2):148–151.
  • POZZI F, FURLANI P, GAZZANIGA A, DAVIS SS, WILDING IR: The Time Clock® system: a new oral dosage form for fast and complete release of drug after a predetermined lag time../. Control. Release (1994) 31(1):99–108.
  • •This paper deals with the Time-Clock® technology, which envisages the unique utilisation of natural waxes and surfactant hydrophobic blends as the release-controlling material for the preparation of a single-unit pulsatile release system. Such a device has shown to correctly perform in vivo on humans as well.
  • WILDING IR, DAVIS SS, POZZI F, FURLANI P, GAZZANIGA A: Enteric coated timed release systems for colonic targeting. Int. Pharm. (1994) 111(1):99–102.
  • STEED KP, HOOPER G, MONTI N, BENEDETTI M, FORNASINI G, WILDING IR: The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system (Time Clock®' system). J. Control. Release (1997) 49(2-3):115–122.
  • KATSTRA WE, PALAZZOLO RD, ROWE CW et al.: Oral dosage forms fabricated by Three Dimensional Printing. .1 Control. Release (2000) 66(1):1–9.
  • ROWE CW, KATSTRA WE, PALAZZOLO RD et al: Multimechanism oral dosage forms fabricated by three dimensional printing'. I Control. Release (2000) 66(1):11–17.
  • LI Y- ZHU J-B: Modulation of combined-release behaviors from a novel 'tablets-in-capsule system'. ./. Control. Release (2004) 95(3):381–389.
  • KOK PJA, VONK P, KOSSEN NW: A particulate pulse-release system and mathematical description with the Maxwell-Stefan theory. J. Control. Release (2000) 66(2-3):293–306.
  • KAO C- CHEN S- SHEU M-T: Lag time method to delay drug release to various sites in the gastrointestinal tract. J. Control. Release (1997) 44(2-3):263–270.
  • NARISAWA S, NAGATA M, DANYOSHI C et al: An organic acid-induced sigmoidal release system for oral controlled-release preparations. Pharm. Res. (1994) 11(1):111–116.
  • •In this paper, the SRS is introduced. This multiparticulate device relies on a peculiar working mechanism consisting in the permeability increase of an outer acrylic film brought about by its interaction with an organic acid contained in the inner layers.
  • NARISAWA S, NAGATA M, ITO T et al: Drug release behavior in gastrointestinal tract of beagle dogs from multiple unit type rate-controlled or time-controlled release preparations coated with insoluble polymer-based film. J. Control. Release (1995) 33(2):253–260.
  • •This paper describes the in vivo performances of SRS in beagle dogs.
  • NARISAWA S, NAGATA M, HIRAKAWA Y, KOBAYASHI M, YOSHINO H: An organic acid-induced sigmoidal release system for oral controlled-release preparations. 2. Permeability enhancement of Eudragit® RS coating led by the physicochemical interactions with organic acid. ./. Pharm. Sci. (1996) 85(2):184–188.
  • NARISAWA S, NAGATA M, HIRAKAWA Y, KOBAYASHI M, YOSHINO H: An organic acid-induced sigmoidal release system for oral controlled preparations. III. Elucidation of the anomalous drug release behaviour through osmotic pumping mechanism. Int. J. Pharm. (1997) 148(1):85–91.
  • WILDING IR, DAVIS SS, BAKHSHAEE M et al: Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation. Pharm. Res. (1992) 9(5):654–657.
  • •In this article, the design and in vivo behaviour of PulsincapTm are dealt with. The system represents the first capsular delivery system for time-controlled release.
  • BINNS JS, BAKHSHAEE M, MILLER CJ, STEVENS HN: Application of a pH independent PEG based hydrogel to afford pulsatile drug delivery. Proceedings of the 20th International Symposium on Controlled Release of Bioactive Materials. Washington, DC, USA (1993): 342.
  • BINNS J, STEVENS HN, MCEWEN J et al.: The tolerability of multiple oral doses of PulsincapTm capsules in healthy volunteers. ./. Control. Release (1996) 38(2-3):151–158.
  • •In this paper, the tolerability related to repeated administrations of placebo PulsincapTm is assessed on volunteers over a 28-day period.
  • WILSON CG, BAKHSHAEE M, STEVENS HN et al.: Evaluation of a gastro-resistant pulsed release delivery system (PulsincapTm) in humans. Drug Del. (1997) 4(3):201–206.
  • HEBDEN JM, WILSON CG, SPILLER RC et al: Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system. Pharm. Res. (1999) 16(7):1087–1092.
  • HEBDEN JM, GILCHRIST PJ, PERKINS AC, WILSON CG, SPILLER RC: Stool water content and colonic drug absorption: contrasting effects of lactulose and codeine. Pharm. Res. (1999) 16(8):1254–1259.
  • STEVENS HNE, WILSON CG, WELLING PG et al: Evaluation of PulsincapTm to provide regional delivery of dofetilide to the human GI tract. Int. J. Pharm. (2002) 236(1-2):27–34.
  • ROSS AC, MACRAE RJ, WALTHER M, STEVENS HNE: Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. ./. Pharm. Pharmacol (2000) 52(8):903–909.
  • MCCONVILLE JT, ROSS AC, CHAMBERS AR et al: The effect of wet granulation on the erosion behaviour of an HPMC-lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation. Eur. Pharm. Biopharm. (2004) 57(3):541–549.
  • SUTCH JCD, ROSS AC, KOCKENBERGER W et al: Investigating the coating-dependent release mechanism of a pulsatile capsule using NMR microscopy. J. Control. Release (2003) 92(3):341–347.
  • KROGEL I, BODMEIER R: Pulsatile drug release from an insoluble capsule body controlled by an erodible plug. Pharm. Res. (1998) 15(3):474–481.
  • KROGEL I, BODMEIER R: Evaluation of an enzyme-containing capsular shaped pulsatile drug delivery system. Pharm. Res. (1999) 16(9):1424–1429.
  • GOHEL MC, SUMITRA GM: Modulation of active pharmaceutical material release from a novel 'tablet in capsule system' containing an effervescent blend. J. Control. Release (2002) 79(1-3):157–164.
  • CRISON JR, SIERSMA PR, TAYLOR MD, ON GL: Programmable oral release technology, Port Systems®: a novel dosage form for time and site specific oral drug delivery. Proceedings of the 22nd International Symposium on Controlled Release of Bioactive Materials. Seattle, WA, USA (1995): 1126.
  • •The design and in vivo behaviour of the PORT system are dealt with in this work. Compared with other capsular devices, this system is based on the time-dependent expulsion of a lipid plug following osmotically-induced water influx into the body.
  • CRISON JR, SIERSMA PR, ON GL: A novel programmable oral release technology for delivering drugs: human feasibility testing using gamma scintigraphy. Proceedings of the 23rd International Symposium on Controlled Release of Bioactive Materials. Kyoto, Japan (1996): 128.
  • •This paper also details the design and in vivo behaviour of the PORT system.
  • LEE WW, O'MAHONY B, BAR-SHALOM D et al: Scintigraphic characterisation of a novel injection-moulded dosage form. Proceedings of the 27th International Symposium on Controlled Release of Bioactive Materials. Paris, France (2000) 8446.
  • •In this paper, the Egalet® technology is proposed in its Burst-Egalet® configuration for pulsatile release. The system envisages an alternative design comprising a cylindrical impermeable outer shell, an inner drug core and two swellable release-controlling plugs sealing each open end.
  • MAHONY B, KOBERLE M, WILSON CG et al: Scintigraphic assessment of a system (Egalet®) for pulsatile peptide delivery in marl. Proceedings of the 28th International Symposium on Controlled Release of Bioactive Materials. San Diego, CA, USA (2001): 6187.
  • •This work also discusses the Egalet® technology proposition in its Burst-Egalet® configuration for pulsatile release.
  • BAR-SHALOM D, SLOT L: An erosion-based approach to the delivery of substances poorly soluble in water. Proceedings of the 30th International Symposium on Controlled Release of Bioactive Materials. Glasgow, UK (2003): 43.
  • SMITH DHG: Pharmacology of cardiovascular chronotherapeutic agents. Am. Hypertens. (2001) 14(911):296s-301s.
  • GUPTA SK, ATKINSON L, THEEUWES F, WONG P, GILBERT PJ, LONGSTRETH J: Pharmacokinetics of verapamil from an osmotic system with delayed onset. Eur. j Pharm. Biopharm. (1996) 42(1):74–81.
  • •This research points out that the release of verapamil hydrochloride from an osmotic once-daily COER-24 formulation can occur over a period of several hours after a 4–5 h delay, thus ideally meeting ischaemic heart disease chronotherapeutic needs. The interest in the above article is augmented by the fact that Covera-HS®, a well-known anti-hypertensive medicinal product available on the US market, is merely based on COER-24 technology.
  • GLASSER SP: Circadian variations and chronotherapeutic implications for cardiovascular management: a focus on COER verapamil. Heart Dis. (1999) 1(4):226–232.
  • WHITE WB, ANDERS RJ, MACINTYRE JM et al: Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Am. I Cardiol (1995) 76(5):375–380.
  • WHITE WB: A chronotherapeutic approach to the management of hypertension. Am. I Hypertens. (1996) 9(411):29s-33s.

Websites

  • http://www.advancispharm.comi newsroomiviewnews.asp?newsId=91 Researchers give early insight into mechanism of action for Advancis' novel biological discovery (Press release).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.